Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2023 Apr 5:41:100626.
doi: 10.1016/j.ctro.2023.100626. eCollection 2023 Jul.

Treating oligodendroglioma - An analysis of a homogeneous 1p/19q-codeleted and isocitrate dehydrogenase-mutant patient cohort

Luisa Allwohn  1 , Josy Wolfgang  1 , Julia Onken  2 , David Wasilewski  2 , Siyer Roohani  1 , Daniel Zips  1   3 , Felix Ehret  1   3   4 , David Kaul  1   3
Affiliations

Treating oligodendroglioma - An analysis of a homogeneous 1p/19q-codeleted and isocitrate dehydrogenase-mutant patient cohort

Luisa Allwohn et al. Clin Transl Radiat Oncol. .

Abstract

Background: Oligodendrogliomas (ODG) are rare, diffusely infiltrating brain tumors, defined by their 1p/19q-codeletion and isocitrate dehydrogenase (IDH) mutation. Herein, we analyze the influence of various tumor and patient characteristics on progression-free survival (PFS) and overall survival (OS) in a homogeneous patient cohort.

Material and methods: Patients treated for a 1p/19q-codeleted and IDH-mutant ODG were evaluated. The patient and tumor characteristics were analyzed for their influence on PFS and OS.

Results: One-hundred-fourteen patients met the inclusion criteria. The median clinical and radiographic follow-up periods were 68.6 and 69.8 months. The median PFS and OS were 66.9 and 236.0 months, respectively. The 2-, 4- and 6-year PFS rates were 89.5%, 76.3%, and 46.0%. The 2-, 4- and 6-year OS rates were 99.0%, 97.9%, and 96.2%. For WHO grade 2 ODG, extent of resection (p = 0.01, hazard ratio (HR) 0.01; p = 0.02, HR 0.02), radiotherapy (p = 0.01, HR < 0.01) and chemotherapy (p = 0.01, HR < 0.01) were associated with a prolonged PFS. For WHO grade 3 ODG, only a combined radiochemotherapy (RCT) lowered the risk of progression in the multivariable analysis (p = 0.02, HR 0.09). Most RCT patients received temozolomide (TMZ) instead of procarbazine, lomustine, and vincristine.

Conclusion: Whereas previous studies often comprise tumors with IDH wild type status and without 1p/19q-codeletion, this homogeneous ODG cohort, as defined by the current WHO classification, demonstrated PFS benefits for various therapies, especially concerning RCT. While this is generally in accordance with comparable studies, more prospective work on homogeneous patient cohorts is required to refine treatment guidelines and to determine the role of TMZ in ODG.

Keywords: IDH mutation; Oligodendroglioma; PCV; Radiochemotherapy; Temozolomide.

PubMed Disclaimer

Conflict of interest statement

The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

Figures

Fig. 1
Fig. 1
Flowchart of cohort screening.
Fig. 2a
Fig. 2a
Progression-free survival.
Fig. 2b
Fig. 2b
Progression-free survival according to WHO grading.
Fig. 3a
Fig. 3a
Overall survival.
Fig. 3b
Fig. 3b
Overall survival according to WHO grading.
Fig. 4
Fig. 4
Progression-free survival according to treatment group.
See this image and copyright information in PMC

References

    1. Louis D.N., Perry A., Reifenberger G., von Deimling A., Figarella-Branger D., Cavenee W.K., et al. The 2016 World Health Organization Classification of Tumors of the Central Nervous System: a summary. Acta Neuropathol. 2016;131(6):803–820. - PubMed
    1. Wick W., Hartmann C., Engel C., Stoffels M., Felsberg J., Stockhammer F., et al. NOA-04 randomized phase III trial of sequential radiochemotherapy of anaplastic glioma with procarbazine, lomustine, and vincristine or temozolomide. J Clin Oncol. 2009;27(35):5874–5880. - PubMed
    1. Wick W., et al. Long-term analysis of the NOA-04 randomized phase III trial of sequential radiochemotherapy of anaplastic glioma with PCV or temozolomide. Neuro Oncol. 2016;18(11):1529–1537. - PMC - PubMed
    1. Weller M., van den Bent M., Preusser M., Le Rhun E., Tonn J.C., Minniti G., et al. EANO guidelines on the diagnosis and treatment of diffuse gliomas of adulthood. Nat Rev Clin Oncol. 2021;18(3):170–186. - PMC - PubMed
    1. van den Bent M.J., Brandes A.A., Taphoorn M.J.B., Kros J.M., Kouwenhoven M.C.M., Delattre J.-Y., et al. Adjuvant procarbazine, lomustine, and vincristine chemotherapy in newly diagnosed anaplastic oligodendroglioma: long-term follow-up of EORTC brain tumor group study 26951. J Clin Oncol. 2013;31(3):344–350. - PubMed

LinkOut - more resources